Analysis of the advantages of early intervention with rasagiline in the treatment of Parkinson's disease

Rasagiline is a selective and irreversible inhibitor of monoamine oxidaseB (MAO-B). It inhibits the decomposition of dopamine and increases the level of dopamine in the brain, thereby improving the motor symptoms of patients with Parkinson's disease. Compared with other MAO-B inhibitors, rasagiline has high selectivity and stable efficacy, and is not prone to serious interactions with food or other drugs, making it suitable for early intervention.

Early use of rasagiline can increase dopamine availability when the disease is still in the mild to moderate stage , thus slowing the progression of motor symptoms. Clinical studies have shown that early intervention not only improves patients' mobility and quality of life, but may also delay the increase in the dose required for long-term use of levodopa and reduce the risk of motor complications caused by drug accumulation, such as the "on-off" phenomenon and dyskinesia.

In addition to motor symptoms, patients with Parkinson's disease are often accompanied by depression, anosmia, sleep disorders and cognitive decline. Early use of rasagiline can alleviate non-motor symptoms to a certain extent, improve cognitive and emotional status by maintaining neurotransmitter balance, and thereby improve overall quality of life. This intervention strategy has a positive impact on patients' self-care ability and mental health.

Another major advantage of early intervention with rasagiline is its high safety and good medication compliance Single use can maintain efficacy and reduce the burden of combined drugs without significantly increasing hypertension or cardiovascular risk. Early and regular use can help patients establish stable medication habits, making it easier to adhere to treatment during long-term management of Parkinson's disease, thereby extending the overall benefit period and reducing the incidence of complications.

Reference materials:https://www.drugs.com/